GeneCast utilizes its proprietary ADPS liquid biopsy technology, achieving a sensitivity of 0.01% for precise cancer gene diagnosis and monitoring. This technology addresses the challenges of early diagnosis and minimal residual disease (MRD) testing, making cancer a manageable condition.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early cancer diagnosis and monitoring of minimal residual disease (MRD) are challenging due to the limitations in sensitivity and multiplexing capabilities of traditional liquid biopsy technologies. Existing methods often lack the precision needed to detect rare cancer gene mutations, hindering timely intervention and effective cancer management.
Solution
GeneCast offers a liquid biopsy technology called ADPS (Allele Discriminating Priming System) designed for precise cancer gene diagnosis and monitoring. ADPS achieves a sensitivity of 0.01%, enabling the detection of rare mutations in liquid biopsies. This technology facilitates early cancer diagnosis and MRD testing, with the goal of making cancer a manageable condition through timely and accurate detection of actionable markers. GeneCast also offers Digital ADPS, which addresses the multiplexing issue, allowing for efficient cancer full cycle management based on high-sensitivity actionable marker analysis.
Target Audience
The primary target audience includes oncologists, pathologists, and diagnostic labs involved in cancer diagnosis, prognosis, and monitoring, as well as pharmaceutical companies developing companion diagnostics.
Features
- ADPS liquid biopsy technology with 0.01% sensitivity for detecting rare cancer gene mutations.
- Digital ADPS technology for efficient cancer full cycle management through high-sensitivity actionable marker analysis.
- ADPS Smart DNA Polymerase diagnostic enzyme.
- geca Diagnostic Enzyme.
- ADPS™ Oncogene Mutation Test.
- ADPS™ Cancer Panel.